These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
172 related articles for article (PubMed ID: 33249196)
1. Glabrescione B delivery by self-assembling micelles efficiently inhibits tumor growth in preclinical models of Hedgehog-dependent medulloblastoma. Infante P; Malfanti A; Quaglio D; Balducci S; De Martin S; Bufalieri F; Mastrotto F; Basili I; Garofalo M; Lospinoso Severini L; Mori M; Manni I; Moretti M; Nicoletti C; Piaggio G; Caliceti P; Botta B; Ghirga F; Salmaso S; Di Marcotullio L Cancer Lett; 2021 Feb; 499():220-231. PubMed ID: 33249196 [TBL] [Abstract][Full Text] [Related]
2. Polymeric glabrescione B nanocapsules for passive targeting of Hedgehog-dependent tumor therapy in vitro. Ingallina C; Costa PM; Ghirga F; Klippstein R; Wang JT; Berardozzi S; Hodgins N; Infante P; Pollard SM; Botta B; Al-Jamal KT Nanomedicine (Lond); 2017 Apr; 12(7):711-728. PubMed ID: 28322108 [TBL] [Abstract][Full Text] [Related]
3. D'Alessandro G; Quaglio D; Monaco L; Lauro C; Ghirga F; Ingallina C; De Martino M; Fucile S; Porzia A; Di Castro MA; Bellato F; Mastrotto F; Mori M; Infante P; Turano P; Salmaso S; Caliceti P; Di Marcotullio L; Botta B; Ghini V; Limatola C Cell Commun Signal; 2019 Aug; 17(1):108. PubMed ID: 31455353 [TBL] [Abstract][Full Text] [Related]
4. Identification of pseudolaric acid B as a novel Hedgehog pathway inhibitor in medulloblastoma. Wei SF; He DH; Zhang SB; Lu Y; Ye X; Fan XZ; Wang H; Wang Q; Liu YQ Biochem Pharmacol; 2021 Aug; 190():114593. PubMed ID: 33964282 [TBL] [Abstract][Full Text] [Related]
5. CAT3, a novel agent for medulloblastoma and glioblastoma treatment, inhibits tumor growth by disrupting the Hedgehog signaling pathway. Chen J; Lv H; Hu J; Ji M; Xue N; Li C; Ma S; Zhou Q; Lin B; Li Y; Yu S; Chen X Cancer Lett; 2016 Oct; 381(2):391-403. PubMed ID: 27495899 [TBL] [Abstract][Full Text] [Related]
6. Effective targeting of Hedgehog signaling in a medulloblastoma model with PF-5274857, a potent and selective Smoothened antagonist that penetrates the blood-brain barrier. Rohner A; Spilker ME; Lam JL; Pascual B; Bartkowski D; Li QJ; Yang AH; Stevens G; Xu M; Wells PA; Planken S; Nair S; Sun S Mol Cancer Ther; 2012 Jan; 11(1):57-65. PubMed ID: 22084163 [TBL] [Abstract][Full Text] [Related]
8. Statins Synergize with Hedgehog Pathway Inhibitors for Treatment of Medulloblastoma. Gordon RE; Zhang L; Peri S; Kuo YM; Du F; Egleston BL; Ng JMY; Andrews AJ; Astsaturov I; Curran T; Yang ZJ Clin Cancer Res; 2018 Mar; 24(6):1375-1388. PubMed ID: 29437795 [No Abstract] [Full Text] [Related]
9. AT-101 inhibits hedgehog pathway activity and cancer growth. Wang J; Peng Y; Liu Y; Yang J; Huang M; Tan W Cancer Chemother Pharmacol; 2015 Sep; 76(3):461-9. PubMed ID: 26113054 [TBL] [Abstract][Full Text] [Related]
10. RITA downregulates Hedgehog-GLI in medulloblastoma and rhabdomyosarcoma via JNK-dependent but p53-independent mechanism. Azatyan A; Gallo-Oller G; Diao Y; Selivanova G; Johnsen JI; Zaphiropoulos PG Cancer Lett; 2019 Feb; 442():341-350. PubMed ID: 30447254 [TBL] [Abstract][Full Text] [Related]
12. Arsenic trioxide inhibits human cancer cell growth and tumor development in mice by blocking Hedgehog/GLI pathway. Beauchamp EM; Ringer L; Bulut G; Sajwan KP; Hall MD; Lee YC; Peaceman D; Ozdemirli M; Rodriguez O; Macdonald TJ; Albanese C; Toretsky JA; Uren A J Clin Invest; 2011 Jan; 121(1):148-60. PubMed ID: 21183792 [TBL] [Abstract][Full Text] [Related]
13. MK-4101, a Potent Inhibitor of the Hedgehog Pathway, Is Highly Active against Medulloblastoma and Basal Cell Carcinoma. Filocamo G; Brunetti M; Colaceci F; Sasso R; Tanori M; Pasquali E; Alfonsi R; Mancuso M; Saran A; Lahm A; Di Marcotullio L; Steinkühler C; Pazzaglia S Mol Cancer Ther; 2016 Jun; 15(6):1177-89. PubMed ID: 26960983 [TBL] [Abstract][Full Text] [Related]
14. Smoothened-activating lipids drive resistance to CDK4/6 inhibition in Hedgehog-associated medulloblastoma cells and preclinical models. Daggubati V; Hochstelter J; Bommireddy A; Choudhury A; Krup AL; Kaur P; Tong P; Li A; Xu L; Reiter JF; Raleigh DR J Clin Invest; 2021 Mar; 131(6):. PubMed ID: 33476305 [TBL] [Abstract][Full Text] [Related]
15. Prostaglandin E1 Inhibits Wu F; Zhang C; Zhao C; Wu H; Teng Z; Jiang T; Wang Y Cancer Res; 2020 Jul; 80(13):2818-2832. PubMed ID: 32371475 [TBL] [Abstract][Full Text] [Related]
16. Developmental phosphoproteomics identifies the kinase CK2 as a driver of Hedgehog signaling and a therapeutic target in medulloblastoma. Purzner T; Purzner J; Buckstaff T; Cozza G; Gholamin S; Rusert JM; Hartl TA; Sanders J; Conley N; Ge X; Langan M; Ramaswamy V; Ellis L; Litzenburger U; Bolin S; Theruvath J; Nitta R; Qi L; Li XN; Li G; Taylor MD; Wechsler-Reya RJ; Pinna LA; Cho YJ; Fuller MT; Elias JE; Scott MP Sci Signal; 2018 Sep; 11(547):. PubMed ID: 30206138 [TBL] [Abstract][Full Text] [Related]
17. A five-gene hedgehog signature developed as a patient preselection tool for hedgehog inhibitor therapy in medulloblastoma. Shou Y; Robinson DM; Amakye DD; Rose KL; Cho YJ; Ligon KL; Sharp T; Haider AS; Bandaru R; Ando Y; Geoerger B; Doz F; Ashley DM; Hargrave DR; Casanova M; Tawbi HA; Rodon J; Thomas AL; Mita AC; MacDonald TJ; Kieran MW Clin Cancer Res; 2015 Feb; 21(3):585-93. PubMed ID: 25473003 [TBL] [Abstract][Full Text] [Related]
18. Druggable glycolytic requirement for Hedgehog-dependent neuronal and medulloblastoma growth. Di Magno L; Manzi D; D'Amico D; Coni S; Macone A; Infante P; Di Marcotullio L; De Smaele E; Ferretti E; Screpanti I; Agostinelli E; Gulino A; Canettieri G Cell Cycle; 2014; 13(21):3404-13. PubMed ID: 25485584 [TBL] [Abstract][Full Text] [Related]
19. mTORC1-Mediated Inhibition of 4EBP1 Is Essential for Hedgehog Signaling-Driven Translation and Medulloblastoma. Wu CC; Hou S; Orr BA; Kuo BR; Youn YH; Ong T; Roth F; Eberhart CG; Robinson GW; Solecki DJ; Taketo MM; Gilbertson RJ; Roussel MF; Han YG Dev Cell; 2017 Dec; 43(6):673-688.e5. PubMed ID: 29103956 [TBL] [Abstract][Full Text] [Related]
20. Identification and characterization of KCASH2 and KCASH3, 2 novel Cullin3 adaptors suppressing histone deacetylase and Hedgehog activity in medulloblastoma. De Smaele E; Di Marcotullio L; Moretti M; Pelloni M; Occhione MA; Infante P; Cucchi D; Greco A; Pietrosanti L; Todorovic J; Coni S; Canettieri G; Ferretti E; Bei R; Maroder M; Screpanti I; Gulino A Neoplasia; 2011 Apr; 13(4):374-85. PubMed ID: 21472142 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]